<DOC>
	<DOCNO>NCT01157169</DOCNO>
	<brief_summary>The object study compare rate extent absorption investigational formulation buprenorphine 8 mg sublingual tablet manufacture Barr Laboratories , Inc. equivalent oral dose commercially available reference product , SubutexÂ® manufacture Reckitt Benckiser , follow overnight fast least 10 hour .</brief_summary>
	<brief_title>Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subject must male nonpregnant , nonbreastfeeding female . Subject must 18 45 year age ( inclusive ) . Subject 's Body Mass Index ( BMI ) must 18 30 ( inclusive ) , subject must weigh minimum 50 kg ( 110 lb ) . Female subject must agree utilize one follow form contraception screen 4 week completion study . Approved forms contraception abstinence , double barrier , IUD place least 30 day prior study drug administration , vasectomized partner , surgically sterile least 6 month , least 2 year postmenopausal . Subject must voluntarily consent participate study provide write informed consent prior completion studyspecific procedure . Subject willing able remain study unit entire duration confinement period return schedule outpatient visit . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease condition , opinion investigator , would jeopardize safety subject validity study result . History presence pancreatitis , bowel obstruction , glaucoma , enlargement prostate , adrenal disease , hyperthyroidism , gallbladder disease . Subjects history cholecystectomy treatment gallbladder disease exclude . Females take oral contraceptive include estrogen progestin combine pill , progestinonly pill , patch , vaginal ring within 28 day prior first dose study medication ; use injectable contraceptive within 6 month first dose ; ever progestational hormone implant . Females take hormone replacement therapy within 60 day prior first dose study medication . Has clinically significant abnormal find physical exam , medical history , ECG , clinical laboratory result screen . History presence allergic adverse response buprenorphine , naltrexone , comparable similar product . Has significantly abnormal diet 4 week precede first dose study medication . Has donate blood plasma within 30 day prior first dose study medication . Has participate another clinical trial within 30 day prior first dose study medication . Has use overthecounter ( OTC ) medication , include cough cold preparation , vitamin , herbal supplement , within 7 day prior first dose study medication . Has use prescription medication within 14 day prior first dose study medication . Has consume beverage food contain alcohol , caffeine/xanthine , poppy seed 48 hour prior first dose study medication consume beverage food contain grapefruit 14 day prior first dose study medication . Has treat know enzymealtering drug , barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . Has smoke use tobacco product within 60 day prior first dose study medication . Has history treatment substance abuse ( include alcohol ) past 5 year . Is female positive pregnancy test result . Has pierce tongue lip pierce within 30 day prior first dose study medication . Has positive urine screen drug abuse . Has positive urine alcohol test ethanol breath test . Has positive test treat hepatitis B , hepatitis C , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy</keyword>
</DOC>